Review



tecovirimat t17026  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    TargetMol tecovirimat t17026
    Tecovirimat T17026, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tecovirimat+t17026/Diphyllin/pmc12924492-92-3-10
    Average 94 stars, based on 1 article reviews
    tecovirimat t17026 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Targeting endolysosomal acidification inhibits poxvirus entry and replication
    Article Snippet: Diphyllin (TN1103) and Tecovirimat ( T17026 ) were obtained from TargetMol.

    Article Title: Targeting endolysosomal acidification inhibits poxvirus entry and replication.
    Article Snippet: Diphyllin (TN1103) and Tecovirimat (T17026) were obtained from TargetMol.



    Similar Products

    tecovirimat t17026  (TargetMol)
    94
    TargetMol tecovirimat t17026
    Tecovirimat T17026, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tecovirimat+t17026/Diphyllin/pmc12924492-92-3-10
    Average 94 stars, based on 1 article reviews
    tecovirimat t17026 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    tecovirimat  (TargetMol)
    94
    TargetMol tecovirimat
    (A-B) Primary human foreskin fibroblasts were infected with VACV at high (MOI = 2, A) or low (MOI = 0.01, B) multiplicity of infection and treated with 10 μM ZW-2038, 40 μg/mL AraC (positive control), or vehicle control. Cell pellets were collected at 24 hpi (A) and 48 hpi (B) and infectious virus titers were quantified by plaque assay. (C) HFFs were infected with MOI = 0.01 of vLGluc in the presence of vehicle or a series of concentration of ZW-2038 or <t>tecovirimat.</t> Gaussia luciferase activities were measured at 24 hpi to determine the EC 50 value. Non-linear regression was used to calculate EC 50 values. (D) HFFs were treated with vehicle or a series of concentration of ZW-2038. CCK8 assay was performed at 24 h post treatment to calculate the CC 50 value. All data represent mean ± SD of at least three independent biological replicates. Statistical analysis was performed using one-way ANOVA with Dunnett’s post hoc test. ****p<0.0001.
    Tecovirimat, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tecovirimat+t17026/Tecovirimat/bio_rxiv__64898__2025__12__18__695249-61-0-4
    Average 94 stars, based on 1 article reviews
    tecovirimat - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    gradient doses  (TargetMol)
    94
    TargetMol gradient doses
    (A-B) Primary human foreskin fibroblasts were infected with VACV at high (MOI = 2, A) or low (MOI = 0.01, B) multiplicity of infection and treated with 10 μM ZW-2038, 40 μg/mL AraC (positive control), or vehicle control. Cell pellets were collected at 24 hpi (A) and 48 hpi (B) and infectious virus titers were quantified by plaque assay. (C) HFFs were infected with MOI = 0.01 of vLGluc in the presence of vehicle or a series of concentration of ZW-2038 or <t>tecovirimat.</t> Gaussia luciferase activities were measured at 24 hpi to determine the EC 50 value. Non-linear regression was used to calculate EC 50 values. (D) HFFs were treated with vehicle or a series of concentration of ZW-2038. CCK8 assay was performed at 24 h post treatment to calculate the CC 50 value. All data represent mean ± SD of at least three independent biological replicates. Statistical analysis was performed using one-way ANOVA with Dunnett’s post hoc test. ****p<0.0001.
    Gradient Doses, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tecovirimat+t17026/Tecovirimat/pm40141361-193-31-35
    Average 94 stars, based on 1 article reviews
    gradient doses - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A-B) Primary human foreskin fibroblasts were infected with VACV at high (MOI = 2, A) or low (MOI = 0.01, B) multiplicity of infection and treated with 10 μM ZW-2038, 40 μg/mL AraC (positive control), or vehicle control. Cell pellets were collected at 24 hpi (A) and 48 hpi (B) and infectious virus titers were quantified by plaque assay. (C) HFFs were infected with MOI = 0.01 of vLGluc in the presence of vehicle or a series of concentration of ZW-2038 or tecovirimat. Gaussia luciferase activities were measured at 24 hpi to determine the EC 50 value. Non-linear regression was used to calculate EC 50 values. (D) HFFs were treated with vehicle or a series of concentration of ZW-2038. CCK8 assay was performed at 24 h post treatment to calculate the CC 50 value. All data represent mean ± SD of at least three independent biological replicates. Statistical analysis was performed using one-way ANOVA with Dunnett’s post hoc test. ****p<0.0001.

    Journal: bioRxiv

    Article Title: Discovery and Characterization of a Hydroxypyridone-3-carboxamide Analog as an Antiviral Lead against Orthopoxviruses

    doi: 10.64898/2025.12.18.695249

    Figure Lengend Snippet: (A-B) Primary human foreskin fibroblasts were infected with VACV at high (MOI = 2, A) or low (MOI = 0.01, B) multiplicity of infection and treated with 10 μM ZW-2038, 40 μg/mL AraC (positive control), or vehicle control. Cell pellets were collected at 24 hpi (A) and 48 hpi (B) and infectious virus titers were quantified by plaque assay. (C) HFFs were infected with MOI = 0.01 of vLGluc in the presence of vehicle or a series of concentration of ZW-2038 or tecovirimat. Gaussia luciferase activities were measured at 24 hpi to determine the EC 50 value. Non-linear regression was used to calculate EC 50 values. (D) HFFs were treated with vehicle or a series of concentration of ZW-2038. CCK8 assay was performed at 24 h post treatment to calculate the CC 50 value. All data represent mean ± SD of at least three independent biological replicates. Statistical analysis was performed using one-way ANOVA with Dunnett’s post hoc test. ****p<0.0001.

    Article Snippet: Tecovirimat was purchased from TargetMol and was dissolved in DMSO for all experiments.

    Techniques: Infection, Positive Control, Control, Virus, Plaque Assay, Concentration Assay, Luciferase, CCK-8 Assay